We are live on
!
Find out more
NI
Nextech Invest Portfolio holdings
AUM
$1.42B
1-Year Est. Return
304.47%
This Fund
S&P 500
This Quarter
Est. Return
+64.19%
1 Year Est. Return
+304.47%
3 Year Est. Return
+631.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.03B
AUM Growth
+$377M
(+57%)
Cap. Flow
+$26.6M
Cap. Flow
% of AUM
2.57%
Top 10 Holdings %
Top 10 Hldgs %
95.46%
Holding
17
New
2
Increased
2
Reduced
2
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
enGene Therapeutics
ENGN
|
+$17M |
| 2 |
Tango Therapeutics
TNGX
|
+$14.9M |
| 3 |
Relay Therapeutics
RLAY
|
+$6.1M |
| 4 |
Monte Rosa Therapeutics
GLUE
|
+$3.76M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arvinas
ARVN
|
+$9.49M |
| 2 |
Kymera Therapeutics
KYMR
|
+$4.19M |
| 3 |
BOLD
Boundless Bio
BOLD
|
+$1.51M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Revolution Medicines
RVMD
$38.1B
| $605M | 58.53% |
7,601,087
| – | – |
|
2
Tyra Biosciences
TYRA
$1.88B
| $107M | 10.31% |
4,055,861
| – | – |
|
|
3
Tango Therapeutics
TNGX
$4.5B
| $64.4M | 6.22% |
7,266,081
+1,732,101
| +31% | +$14.9M |
|
4
Oric Pharmaceuticals
ORIC
$1.11B
| $58.6M | 5.66% |
7,162,637
| – | – |
|
|
5
Relay Therapeutics
RLAY
$4.22B
| $39.8M | 3.85% |
4,701,506
+855,097
| +22% | +$6.1M |
|
6
Zymeworks
ZYME
$1.78B
| $29.3M | 2.84% |
1,113,946
| – | – |
|
|
ALMS
7
Alumis Inc
ALMS
$3.47B
| $28.5M | 2.75% |
2,915,998
| – | – |
|
|
8
Kymera Therapeutics
KYMR
$9.38B
| $21.7M | 2.1% |
278,896
-62,013
| -18% | -$4.19M |
|
|
9
enGene Therapeutics
ENGN
$129M
| $19.2M | 1.86% |
+2,124,943
| New | +$17M |
|
|
MRSN
10
DELISTED
Mersana Therapeutics
MRSN
| $14M | 1.35% |
482,689
| – | – |
|
11
Cullinan Oncology
CGEM
$1.01B
| $11.8M | 1.14% |
1,141,145
| – | – |
|
12
Context Therapeutics
CNTX
$56.5M
| $10.9M | 1.05% |
7,419,355
| – | – |
|
13
ARS Pharmaceuticals
SPRY
$741M
| $7.7M | 0.74% |
660,703
| – | – |
|
|
14
Arvinas
ARVN
$518M
| $6.4M | 0.62% |
539,394
-869,000
| -62% | -$9.49M |
|
|
SLN
15
Silence Therapeutics
SLN
$516M
| $5.79M | 0.56% |
952,400
| – | – |
|
|
16
Monte Rosa Therapeutics
GLUE
$1.96B
| $4.38M | 0.42% |
+279,237
| New | +$3.76M |
|
|
BOLD
17
Boundless Bio
BOLD
$56M
| – | – |
-1,228,069
| Closed | -$1.51M |
|
Similar funds
KCM
BC
WC
IHG
PTC
PPC
KCMH
APCM
Nextech Invest's Q4 2025 Portfolio in Review
As of Q4 2025, Nextech Invest held 17 positions worth $1.03B, up 57% from $657M the previous quarter. Its ten largest holdings account for 95% of the portfolio.
Nextech Invest's Q4 2025 filing shows 2 new, 2 increased, 2 reduced and 1 closed positions. Its largest new stake was enGene Therapeutics: 2,124,943 shares worth $19.2M. The largest sale was Arvinas, an estimated $9.49M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Nextech Invest's largest Q4 2025 buy was enGene Therapeutics: 2,124,943 shares worth $19.2M.
- Nextech Invest added most to Tango Therapeutics in Q4 2025, an estimated $14.9M increase.
- Nextech Invest's biggest Q4 2025 reduction was Arvinas, cutting an estimated $9.49M.
- Nextech Invest fully exited Boundless Bio in Q4 2025, selling an estimated $1.51M.
- Nextech Invest's ten largest holdings make up 95% of its $1.03B portfolio in Q4 2025.
- Nextech Invest opened 2 new positions and closed 1 in Q4 2025.
- Nextech Invest's portfolio value rose 57% quarter-over-quarter to $1.03B.
Based on Nextech Invest's 13F filing for Q4 2025, filed 17 Feb 2026.